{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-24-000128","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.074779+00:00","generated_at":"2026-05-29T03:06:42.775073+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Senti Bio doses first patient in SN301A CAR-NK trial for liver cancer in China","bullets":["First patient dosed in SN301A pilot trial for advanced GPC3-expressing HCC in mainland China.","SN301A is SENTI-301A CAR-NK product candidate manufactured and developed by Celest Therapeutics.","Open-label, single-center study (NCT06652243) evaluating safety, pharmacokinetics, and anti-tumor activity.","Three dose levels administered in 28-day cycles with lymphodepletion conditioning.","Over 40% of global HCC cases occur in China; Senti retains rights outside Greater China."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-24-000128","json":"https://secwatch.observer/filing/0001854270-24-000128.json","markdown":"https://secwatch.observer/filing/0001854270-24-000128.md","text":"https://secwatch.observer/filing/0001854270-24-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/0001854270-24-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/snti-20241216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:06:42.775073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}